(2023). Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England. Int J Chron Obstruct Pulmon Dis, 18, 231-245. http://doi.org/10.2147/copd.s389281
. Adrenal Cortex Hormones
(2022). Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy. Int J Chron Obstruct Pulmon Dis, 17, 2187-2200. http://doi.org/10.2147/copd.s378649
. (2022). Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β(2)-agonist dual therapy in a primary care setting in England. Bmj Open Respir Res, 9. http://doi.org/10.1136/bmjresp-2022-001243
. (2022). Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety. Int J Chron Obstruct Pulmon Dis, 17, 1975-1986. http://doi.org/10.2147/copd.s378486
. (2022). Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England. Int J Chron Obstruct Pulmon Dis, 17, 1781-1795. http://doi.org/10.2147/copd.s365480
. (2022). Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England. Int J Chron Obstruct Pulmon Dis, 17, 1455-1466. http://doi.org/10.2147/copd.s338436
. (2022). Discontinuation of Inhaled Corticosteroids from Triple Therapy in COPD: Effects on Major Outcomes in Real World Clinical Practice. Copd, 19, 133-141. http://doi.org/10.1080/15412555.2022.2045265
.